Replies to This Discussion

Permalink Reply by Jan on April 21, 2013 at 8:32pm

This insulin does sound like what we need. We need to stop the lows that can occur even with frequent basal testing. Our Type 1 seems to be extremely sensitive to the slightest amount of extra exercise (I am talking about walking, not planned exercise which we can easily take into account). I can see using it for meals and to correct highs. However, they definitely need to make smaller cannisters using much smaller amounts. But my question is: If you are using Lantus as your basal insulin, how do you prevent lows due to Lantus? Or highs. You can still go low on your basal insulin. And once you give a Lantus dose you're stuck with it; you can temp basal up or down as with the pump. You would be better off keeping the pump for basal insulin and using Affreza for meals and highs. I will be keeping my eye on this product after reading your amazing account of your experience. Thanks for informing us. I had thought inhaled insulin was not something worthwhile to consider.

• ▶ Reply

Permalink Reply by Simon Carter on April 21, 2013 at 10:22pm

I think we would all agree than insulin shots are the least painful aspect of diabetes. For me, finger pick blood tests are the worst.

Here is an interesting read about Exubera (the failed inhaled insulin),
http://curetype1diabetes.blogspot.com.au/2006_01_01_archive.html . In short, a cough, decrease in lung function, associated with a lower overall hypoglycemia rate but higher severe hypoglycemia rate, appearance of Exubera antibodies.

• ▶ Reply

Permalink Reply by Judy on April 21, 2013 at 10:41pm

If I recall correctly, Afrezza has failed to "pass" FDA twice...

• ▶ Reply

Permalink Reply by Jan on April 23, 2013 at 8:37pm

They should skip application to FDA altogether and try to market the drug in Europe first. FDA will hold release up for years. Once the drug is marketed in Europe it will be easier to get it through the FDA.... hopefully. This appears to be NOTHING like Exubera. Far superior; a true prandial insulin that mimics first-phase insulin response. I have seen nothing on Tu about Oral-lyn which is absorbed through buccal cavity of the mouth, bypassing the lungs entirely. That has been marketed overseas, not in Europe, in Latin America.

• ▶ Reply

Permalink Reply by Simon Carter on April 23, 2013 at 6:03pm

We have added modelling for Afreeza to ManageBGL's prediction system, and here are two sample scenarios:
http://www.managebgl.com/scenarios/afreeza-vs-humalog-novolog-novor...

• ▶ Reply

Permalink Reply by Jan on April 23, 2013 at 9:08pm

One more concern..... If one should give the incorrect prandial dosage with Afrezza, would there be problems with hypos and not enough time to assess the situation and retrench? ICRs are more stable than basals but... different amounts of insulin for different foods, different ICRs based on exercise.... there is variability in bolus dosing as well. Working so quickly, at what point do you assess and either give carbs if necessary. We have been trained to test two hours after each meal and assess if more insulin is needed or more carbs. You would be surprised how the same meal different days does not yield the same results. This insulin is so quick; at what point do you check to see if your dosing was, in fact, accurate?

• ▶ Reply

• ‹ Previous
• 1
• …
• 6
• 7
• 8
• Next ›
• Page